Biosimilar and Interchangeable Biologics Give You More Treatment Options

biosimilar medications, diabetes, cancer, Crohn's disease, colitis, rheumatoid arthritis, psoriasis

If your email program has trouble displaying this email, view as a webpage. Biosimilar and Interchangeable Biologics: More Treatment Choices   The U.S. Food and Drug Administration has approved biosimilar medications to treat conditions such as cancer, diabetes, Crohn's disease, colitis, rheumatoid arthritis, psoriasis, and more. Recently, the FDA approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn), as a diabetes treatment. Biologics include medicines that generally come from living organisms. A biosimilar is a biologic that is highly similar to, and has no clinically meaningful differences from, another biologic that's already FDA-approved.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA